Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. (NASDAQ: GNPX) is a pioneering clinical-stage gene therapy company committed to transforming the landscape of cancer and diabetes treatments. The company's mission is to address the unmet medical needs of a growing population of patients worldwide through the development of innovative immunogene therapies. Genprex's flagship product, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is at the forefront of its oncology program and is currently being evaluated in three clinical trials targeting non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Oncoprex® Delivery System, Genprex's proprietary platform, encapsulates gene-expressing plasmids using lipid-based nanoparticles. This systemic, non-viral method enables the intravenous delivery of tumor suppressor genes to cancer cells, which then express proteins that were deficient in the tumor. Reqorsa Immunogene Therapy has shown promise by re-establishing pathways for programmed cell death, interrupting cancer cell signaling, and modulating immune responses.
The company's recent achievements include securing new patents and receiving FDA Fast Track and Orphan Drug designations for its clinical programs. Specifically, the Acclaim-2 and Acclaim-3 studies are exploring the potential of Reqorsa in combination with immune checkpoint inhibitors like Keytruda® and Tecentriq®. These trials aim to provide new therapeutic options for patients with advanced-stage lung cancers who have limited treatment alternatives.
In addition to its oncology initiatives, Genprex is advancing a novel gene therapy approach for diabetes. Using an AAV vector, the company delivers Pdx1 and MafA genes directly to the pancreas to transform alpha cells into beta-like cells capable of producing insulin. This method shows promise for both Type 1 and Type 2 diabetes and aims to offer a new lifeline for patients with these conditions.
Genprex collaborates with renowned institutions and industry leaders to further its research and development pipeline. The company's commitment to innovation and patient-centric solutions positions it as a significant player in the gene therapy landscape.
Latest News:
- March 12, 2024 - Genprex announces new patent grants in South Korea for Reqorsa® Immunogene Therapy.
- March 19, 2024 - Genprex enters into agreements for the sale and issuance of shares, expecting gross proceeds of $6.5 million.
- April 2, 2024 - Positive preclinical data for NPRL2 gene therapy presented at AACR Annual Meeting.
- April 3, 2024 - Multiple new trial sites added for Acclaim-3 study in extensive-stage small cell lung cancer.
- April 9, 2024 - Research collaborators present positive preclinical data supporting Reqorsa and NPRL2 therapies.
- May 8, 2024 - Genprex announces the passing of its co-founder and CEO Rodney Varner.
- May 14, 2024 - First patient dosed in Phase 1 of Acclaim-3 clinical study for Reqorsa® and Tecentriq® combination therapy.
Genprex, Inc. (NASDAQ: GNPX), a gene therapy company focused on cancer and diabetes treatments, has announced its participation in several investor conferences throughout May. Presentations will be led by President and CEO Rodney Varner.
Key Events:
- Diamond Equity Emerging Growth Invitational: May 11, 11-11:25 a.m. ET
- Benzinga Small Cap Conference: May 14, 12:45-1:05 p.m. ET
- CEO Roadshow Webinar: Weekly on Thursdays from April 22 to June 10, 11-11:30 a.m. ET
Recordings will be available post-conference on Genprex's website.
Genprex, Inc. (GNPX) announced an amendment to its License Agreement with a major cancer research center in Houston, granting the company an exclusive worldwide license for six patents and one patent application. The Newly Licensed IP aims to enhance treatment for non-small cell lung cancer (NSCLC) by combining TUSC2 therapy with EGFR inhibitors or other therapies. The lead candidate, REQORSA™, has been granted Fast Track Designation by the FDA for NSCLC in conjunction with Tagrisso. Genprex is set to launch Acclaim-1 and Acclaim-2 clinical trials combining REQORSA with other therapies.
Genprex (NASDAQ: GNPX) announced receiving centralized Institutional Review Board (IRB) approval for the Acclaim-1 clinical trial protocol targeting non-small cell lung cancer (NSCLC). This open-label, multi-center Phase 1/2 trial will evaluate the combination of REQORSA™ immunogene therapy and AstraZeneca’s Tagrisso® in late-stage NSCLC patients with mutated EGFRs. With FDA Fast Track Designation already secured, Genprex aims to initiate the trial at 15 U.S. sites, enrolling approximately 92 patients, and an interim analysis will occur after 25 clinical events.
Genprex, Inc. (NASDAQ: GNPX) has initiated the recruitment of clinical trial sites for the Acclaim-2 trial, targeting late-stage non-small cell lung cancer (NSCLC) patients. This Phase 1/2 open-label trial will examine the combination of REQORSA™ immunogene therapy and Merck's Keytruda in patients with low PD-L1 expression. Approximately 150 patients at around 15 sites will be enrolled in this adaptive trial. The protocol may be adjusted based on investigator feedback, aiming to provide new treatment options for NSCLC patients.
Genprex, Inc. (NASDAQ: GNPX) announced its President and CEO, Rodney Varner, will participate in a weekly webinar series hosted by CEO Roadshow from April 22 to June 10, 2021.
The webinars will occur every Thursday from 11-11:30 a.m. EDT, providing an overview of the company and its gene therapy developments for cancer and diabetes. Attendees can ask questions after each presentation, and replays will be available on the company's website. Genprex focuses on innovative therapies, notably its lead candidate REQORSA™ for non-small cell lung cancer.
Genprex, Inc. (NASDAQ: GNPX) has been awarded the inaugural "License of the Year" from the University of Pittsburgh Innovation Institute for its diabetes gene therapy, GPX-002. This therapy aims to convert pancreas alpha cells into insulin-producing beta-like cells, potentially curing diabetes. Preclinical results show promise with mice, indicating blood glucose levels normalized for up to four months. The award recognizes the innovative work of Dr. George Gittes at UPMC, enhancing the company's reputation in gene therapy.
Genprex, Inc. (GNPX) announced promising preclinical data for its TUSC2 immunogene therapy (REQORSA™) presented at the AACR 2021 meeting. The data indicate that REQORSA, combined with chemotherapy and immunotherapies, enhances treatment efficacy for non-small cell lung cancer (NSCLC), particularly in cases resistant to existing therapies. Upcoming Acclaim-1 and Acclaim-2 clinical trials aim to explore these combinations further. The research highlights REQORSA's potential to address unmet needs in NSCLC treatment.
Genprex, Inc. (NASDAQ: GNPX) announces that Michael Redman, its Executive VP and COO, will present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean from April 6-9, 2021. This event will feature over 80 company presentations and more than 50 expert panel discussions focusing on advancements in cell and gene therapy. Genprex aims to develop innovative therapies for cancer and diabetes, with its lead product candidate, REQORSA™, currently evaluated for non-small cell lung cancer. Registration is available for credentialed investors and media.
Genprex has announced that preclinical data on TUSC2 immunogene therapy (REQORSA™) will be presented at the AACR 21 meeting from April 9-14, 2021. This therapy aims to improve treatment outcomes for non-small cell lung cancer (NSCLC) by enhancing the efficacy of chemotherapy and overcoming resistance to osimertinib. The upcoming Acclaim-1 and Acclaim-2 clinical trials will evaluate REQORSA in combination with AstraZeneca’s Tagrisso® and Merck's Keytruda®. The presentations are expected to attract attention from leading cancer researchers.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, will present at the Spring 2021 Oncology Investor Conference from March 29 to April 2, 2021. President and CEO Rodney Varner will deliver a virtual company overview on March 29 at 2 p.m. EDT, focusing on innovative gene therapies for non-small cell lung cancer and diabetes. Genprex's lead candidate, REQORSA™, has received Fast Track Designation by the FDA for treating NSCLC in combination with osimertinib, aiming to improve treatment options for patients with limited alternatives.
FAQ
What is the current stock price of Genprex (GNPX)?
What is the market cap of Genprex (GNPX)?
What is Genprex's main focus?
What is Reqorsa Immunogene Therapy?
How does the Oncoprex® Delivery System work?
What recent achievements has Genprex made?
What is the status of Genprex's clinical trials?
What are the implications of Genprex's recent patent grants?
What is Genprex's approach to diabetes treatment?
How does Reqorsa enhance current cancer treatments?
Who are Genprex's key collaborators?
How has Genprex adapted to recent leadership changes?
